Genecast (Taizhou) Biotechnology

CN

HOME

Products / Services

Partnering

Publications: SCI-indexed journal articles; Oncology academic conference

Request

About Us: Our Story; Milestones; Management Team; Certification; News; Contact Us

GenecastAims to increase patients' life span through personalized treatment.

Based on high-throughput sequencing,
bioinformatics and the latest translational medicine.

Read More

WE PROVIDE PRECISION DIAGNOSITIC SOLUTIONS GLOBAL WISE

Hospital

Clinical diagnostic report
Clinical research support
From sample to report total clinical solution

Independent Clinical Lab

Diagnostic kits
Bioinformatics Reporting systems
From sample to report workflow solution

Pharma & CRO

Biomarker discovery
Patient profiling & sub-typing
Multi-omics testing & research & CDx collaboration

Ongoing clinical studies

APEX

CAREMЕ

Gross floor area

>
5,000

Hospitals

>
60

*By June，2025

Our Products & Services

Therapy Selection

Genecast IVD Focus，Genecast Pan-Cancer Focus，Genecast IVD - KNBP，etc.

Prognosis and Monitoring

Genecast MRD MinerVa，Genecast MinerVa PRIME，Genecast IVD - MammaPrint

Early Screening

Genecast THEMIS

Read More

Select Country / Region

Launching soon ! ...

All In One (AIO) Fully Automated System

All In One (AIO) Fully Automated System

Our Partners

Read More

Genecast News

December 26 , 2025 Genecast Group and Sequanta Technologies Partner to Forge a New Chapter in Pharmaceutical Services and Companion Diagnostics Collaboration

Read More

Genecast Publications

Quantitative and dynamic ctDNA as a biomarker of response and survival in lung squamous cancer patients receiving immunochemotherapy or chemotherapy alone

Multi-omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma

Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)

February 27, 2025

An Expanding Universe of Mutational Signatures and Its Rapid Evolution in Single-Stranded RNA Viruse

January 31, 2025

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study

December 27, 2024

Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations

December 25, 2024

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC

November 25, 2024

Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial

August 23, 2024

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma

Read More